Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

25
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
25
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

34
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
34
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world.

JHEP reports : innovation in hepatology·2025
Same author

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg).

Gut·2024
Same author

Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024
Same author

Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.

United European gastroenterology journal·2023
Same author

Corrected and republished from: Metabolic associated liver disease.

Panminerva medica·2023
Same author

Male infertility and alcohol use disorder identification test.

Minerva endocrinology·2023

Related Experiment Video

Updated: Apr 25, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

628

Inflammatory bowel diseases: Current problems and future tasks.

Giovanni C Actis1, Rinaldo Pellicano1, Floriano Rosina1

  • 1Giovanni C Actis, Floriano Rosina, Division of Gastro-Hepatology, Ospedale Gradenigo, 10153 Torino, Italy.

World Journal of Gastrointestinal Pharmacology and Therapeutics
|August 19, 2014
PubMed
Summary

Real-world inflammatory bowel disease (IBD) practice reveals common use of mesalamines and steroids for remission. IBD, particularly Crohn's disease, is frequently associated with psoriasis, suggesting a "barrier organ disease" model for personalized treatment.

Keywords:
Barrier organsFuture trends in inflammatory bowel diseaseImmunopharmacologyInflammatory bowel diseaseMicrobiome

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

8.4K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

6.7K

Related Experiment Videos

Last Updated: Apr 25, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

628
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

8.4K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

6.7K

Area of Science:

  • Gastroenterology and Immunology
  • Dermatology
  • Public Health

Background:

  • Current understanding of inflammatory bowel disease (IBD) relies heavily on clinical trials and epidemiology.
  • Real-world clinical practice data for IBD management remains under-explored.

Purpose of the Study:

  • To analyze real-world treatment patterns and comorbidities in a cohort of IBD patients.
  • To investigate the association between IBD and other immune-mediated diseases, particularly psoriasis.

Main Methods:

  • Retrospective analysis of 64 out-patients with IBD (26 Crohn's disease, 38 ulcerative colitis) seen within the last year.
  • Review of prescription data for remission induction and maintenance therapies.
  • Assessment of co-occurring immunologic diseases.

Main Results:

  • Mesalamines and steroids were the primary agents for inducing remission in ulcerative colitis and Crohn's disease.
  • Adherence and the use of third-line therapies (antibiotics, NSAIDs, biologics) were noted during maintenance.
  • A significant proportion of patients had accompanying immunologic diseases, with psoriasis being the most common comorbidity in Crohn's disease (34% CD, 23% UC).

Conclusions:

  • The observed association between IBD and psoriasis supports the concept of "barrier organ diseases," encompassing conditions affecting epithelial surfaces.
  • IBD is proposed as a polyfactorial/syndromic disorder with multiple immune system involvements.
  • Stratifying IBD into distinct pathogenic categories could enable subtype-specific treatments, moving beyond single-cytokine targeting for personalized medicine.